Loading...

BeiGene

BST:49B
Snowflake Description

High growth potential with excellent balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
49B
BST
$7B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

BeiGene, Ltd. develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer. The last earnings update was 4 days ago. More info.


Add to Portfolio Compare Print
49B Share Price and Events
7 Day Returns
0%
BST:49B
0.6%
DE Biotechs
-0.4%
DE Market
1 Year Returns
-
BST:49B
5.3%
DE Biotechs
-8.3%
DE Market
49B Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
BeiGene (49B) 0% 0% 4.5% - - -
DE Biotechs 0.6% 1.7% -6.4% 5.3% 66% 81.1%
DE Market -0.4% 1.6% -6.2% -8.3% 24.8% 50.5%
1 Year Return vs Industry and Market
  • No trading data on 49B.
  • No trading data on 49B.
Price Volatility
49B
Industry
5yr Volatility vs Market
Related Companies

Sorry, no analysis for BeiGene's competitors could be found in our database.

Value

 Is BeiGene undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of BeiGene to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for BeiGene.

BST:49B Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 9 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8.6%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.5%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for BST:49B
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.5%
Equity Risk Premium S&P Global 9.5%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 0.83
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.832 (1 + (1- 21%) (2.72%))
0.85
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.85
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.54% + (0.85 * 9.46%)
8.58%

Discounted Cash Flow Calculation for BST:49B using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for BeiGene is arrived at by discounting future cash flows to their present value using the 2 stage method. We use analyst's estimates of cash flows going forward 5 years for the 1st stage, the 2nd stage assumes the company grows at a stable rate into perpetuity.

BST:49B DCF 1st Stage: Next 5 year cash flow forecast
2019 2020 2021 2022 2023
Levered FCF (USD, Millions) -516.00 -469.00 79.65 542.00 628.72
Source Analyst x2 Analyst x2 Analyst x1 Analyst x1 Est @ 16%, capped from 80.46%
Present Value
Discounted (@ 8.58%)
-475.22 -397.79 62.22 389.91 416.55
Present value of next 5 years cash flows $-4.33
BST:49B DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2023 × (1 + g) ÷ (Discount Rate – g)
= $628.72 × (1 + 0.54%) ÷ (8.58% – 0.54%)
$7,862.20
Present Value of Terminal Value = Terminal Value ÷ (1 + r)5
= $7,862.20 ÷ (1 + 8.58%)5
$5,208.99
BST:49B Total Equity Value
Calculation Result
Total Equity Value = Present value of next 5 years cash flows + Terminal Value
= $-4.33 + $5,208.99
$5,204.66
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $5,204.66 / 59.33
$7.94
BST:49B Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in BST:49B represents 0.09047x of NasdaqGS:BGNE
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.09047x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 87.73 x 0.09047
€7.94
Value per share (EUR) From above. €7.94
Current discount Discount to share price of €10.97
= -1 x (€10.97 - €7.94) / €7.94
-38.2%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of BeiGene is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for BeiGene's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are BeiGene's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
BST:49B PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-09-30) in USD $-9.77
NasdaqGS:BGNE Share Price ** NasdaqGS (2018-08-15) in USD $121.25
Europe Biotechs Industry PE Ratio Median Figure of 25 Publicly-Listed Biotechs Companies 26.95x
Germany Market PE Ratio Median Figure of 414 Publicly-Listed Companies 18.14x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of BeiGene.

BST:49B PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:BGNE Share Price ÷ EPS (both in USD)

= 121.25 ÷ -9.77

-12.4x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • BeiGene is loss making, we can't compare its value to the Europe Biotechs industry average.
  • BeiGene is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does BeiGene's expected growth come at a high price?
Raw Data
BST:49B PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -12.4x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 9 Analysts
39.7%per year
Europe Biotechs Industry PEG Ratio Median Figure of 16 Publicly-Listed Biotechs Companies 1.56x
Germany Market PEG Ratio Median Figure of 271 Publicly-Listed Companies 1.42x

*Line of best fit is calculated by linear regression .

BST:49B PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= -12.4x ÷ 39.7%

-0.31x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • BeiGene is loss making, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on BeiGene's assets?
Raw Data
BST:49B PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-09-30) in USD $34.63
NasdaqGS:BGNE Share Price * NasdaqGS (2018-08-15) in USD $121.25
Germany Biotechs Industry PB Ratio Median Figure of 13 Publicly-Listed Biotechs Companies 2.44x
Germany Market PB Ratio Median Figure of 553 Publicly-Listed Companies 1.91x
BST:49B PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:BGNE Share Price ÷ Book Value per Share (both in USD)

= 121.25 ÷ 34.63

3.5x

* Primary Listing of BeiGene.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • BeiGene is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess BeiGene's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. BeiGene has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is BeiGene expected to perform in the next 1 to 3 years based on estimates from 9 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
39.7%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is BeiGene expected to grow at an attractive rate?
  • BeiGene's earnings growth is expected to exceed the low risk savings rate of 0.5%.
Growth vs Market Checks
  • BeiGene's earnings growth is expected to exceed the Germany market average.
  • BeiGene's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
BST:49B Future Growth Rates Data Sources
Data Point Source Value (per year)
BST:49B Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 9 Analysts 39.7%
BST:49B Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 9 Analysts 48.7%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 50.1%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 23.7%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 5.6%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
BST:49B Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 9 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
BST:49B Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2022-12-31 1,558 130 211 3
2021-12-31 760 -87 -199 4
2020-12-31 372 -487 -564 7
2019-12-31 249 -493 -619 9
2018-12-31 205 -461 -559 8
BST:49B Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-09-30 174 -260 -508
2018-06-30 340 -121 -246
2018-03-31 271 -56 -147
2017-12-31 255 13 -96
2017-09-30 220 -107 -31
2017-06-30 0 -138 -184
2017-03-31 0 -105 -148
2016-12-31 1 -90 -119
2016-09-30 6 -80 -109
2016-06-30 7 -66 -87
2016-03-31 8 -56 -69
2015-12-31 9 -40 -57

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • BeiGene's earnings are expected to grow significantly at over 20% yearly.
  • BeiGene's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
BST:49B Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 9 Analyst Estimates (S&P Global) See Below

All data from BeiGene Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BST:49B Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2022-12-31 2.20 10.94 -8.50 4.00
2021-12-31 -6.01 -0.77 -10.71 4.00
2020-12-31 -10.75 -7.59 -14.69 5.00
2019-12-31 -11.30 -10.35 -13.76 7.00
2018-12-31 -10.18 -9.01 -11.31 8.00
BST:49B Past Financials Data
Date (Data in USD Millions) EPS *
2018-09-30 -9.77
2018-06-30 -5.11
2018-03-31 -3.29
2017-12-31 -2.30
2017-09-30 -0.80
2017-06-30 -4.97
2017-03-31 -4.19
2016-12-31 -3.84
2016-09-30 -4.45
2016-06-30 -4.80
2016-03-31 -5.70
2015-12-31 -6.71

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if BeiGene will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess BeiGene's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
BeiGene has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has BeiGene performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare BeiGene's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • BeiGene does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare BeiGene's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare BeiGene's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
BeiGene's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from BeiGene Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BST:49B Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-09-30 174.03 -507.77 150.31 88.38
2018-06-30 340.04 -246.35 117.13
2018-03-31 270.93 -147.08 82.75
2017-12-31 254.69 -96.03 62.60
2017-09-30 220.21 -31.38 43.52 49.91
2017-06-30 0.00 -184.26 32.61
2017-03-31 0.39 -147.84 25.73
2016-12-31 1.07 -119.22 20.10
2016-09-30 5.75 -108.87 14.71 26.73
2016-06-30 7.13 -87.37 12.01
2016-03-31 8.11 -68.89 9.31
2015-12-31 8.82 -57.10 7.31
2015-09-30 5.52 -33.60 5.99
2015-06-30 10.64 -29.36 7.77
2015-03-31 11.84 -26.11 7.31
2014-12-31 13.04 -18.28 6.93
2013-12-31 11.15 -7.49 3.14

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if BeiGene has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if BeiGene has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if BeiGene improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess BeiGene's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
BeiGene has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is BeiGene's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up BeiGene's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • BeiGene is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • BeiGene's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of BeiGene's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 11.1x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from BeiGene Company Filings, last reported 1 month ago.

BST:49B Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-09-30 1,983.43 195.97 2,033.76
2018-06-30 1,226.67 209.75 1,369.63
2018-03-31 1,358.72 173.68 1,464.02
2017-12-31 681.94 164.72 837.52
2017-09-30 764.49 158.35 757.44
2017-06-30 270.17 152.73 407.43
2017-03-31 308.42 19.90 327.48
2016-12-31 352.91 17.28 368.17
2016-09-30 187.83 18.03 203.62
2016-06-30 220.05 10.55 226.62
2016-03-31 243.10 6.21 247.23
2015-12-31 74.32 20.79 100.49
2015-09-30 100.08 20.63 121.34
2015-06-30 109.91 14.05 126.67
2015-03-31 25.77 13.84 44.40
2014-12-31 25.77 13.84 44.40
2013-12-31 -36.96 35.98 3.93
  • BeiGene's level of debt (9.9%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if BeiGene's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • BeiGene has sufficient cash runway for more than 3 years based on current free cash flow.
  • BeiGene has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 53.9% each year.
X
Financial health checks
We assess BeiGene's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. BeiGene has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is BeiGene's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from BeiGene dividends. Estimated to be 0% next year.
If you bought €2,000 of BeiGene shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate BeiGene's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate BeiGene's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
BST:49B Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 9 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.8%
Germany Market Average Dividend Yield Market Cap Weighted Average of 326 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.5%
Germany Top 25% Dividend Yield 75th Percentile 3.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

BST:49B Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2022-12-31
2021-12-31
2020-12-31 0.00 2.00
2019-12-31 0.00 2.00
2018-12-31 0.00 3.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as BeiGene has not reported any payouts.
  • Unable to verify if BeiGene's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of BeiGene's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as BeiGene has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of BeiGene's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess BeiGene's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can BeiGene afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. BeiGene has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of BeiGene's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
John Oyler
COMPENSATION $10,291,525
AGE 50
TENURE AS CEO 8.8 years
CEO Bio

Mr. John V. Oyler Co-Founded BeiGene, Ltd. and has been its Chief Executive Officer since 2010. Mr. Oyler Co-founded BioDuro, LLC and served as its Chief Executive Officer and President from 2005 to 2009. He co-founded Telephia, Inc. (now Nielsen Mobile, Inc.) and served as its President from 1997 to 2002. He served as Chief Executive Officer of Galenea Corp. from 2002 to 2004. Mr. Oyler served as the Co-Chief Executive Officer of Genta, Inc., from 1997 to 1998. Mr. Oyler began his career as a management consultant at McKinsey & Company. Mr. Oyler serves as the Chairman at BeiGene, Ltd. and has been its Director since 2010. Mr. Oyler earned an MBA from the Stanford Graduate School of Business and a Bachelor of Science degree in Mechanical Engineering from MIT.

CEO Compensation
  • John's compensation has increased whilst company is loss making.
  • John's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the BeiGene management team in years:

3.3
Average Tenure
51
Average Age
  • The tenure for the BeiGene management team is about average.
Management Team

John Oyler

TITLE
Co-Founder
COMPENSATION
$10M
AGE
50
TENURE
8.8 yrs

Howard Liang

TITLE
CFO & Chief Strategy Officer
COMPENSATION
$4M
AGE
55
TENURE
3.3 yrs

Amy Peterson

TITLE
Chief Medical Officer of Immuno-Oncology
COMPENSATION
$3M
AGE
51
TENURE
2.3 yrs

Jane Huang

TITLE
Chief Medical Officer - Hematology
COMPENSATION
$3M
AGE
45
TENURE
2.2 yrs

Xiaobin Wu

TITLE
President & General Manager of China
TENURE
0.5 yrs

Xiaodong Wang

TITLE
Co-Founder
COMPENSATION
$3M
AGE
55
TENURE
8.8 yrs

Maggie Liu

TITLE
Head of Operations and Vice President

Lucy Li

TITLE
Investor Contact

Scott Samuels

TITLE
Senior VP & General Counsel

Luo Lusong

TITLE
Head of Discovery Biology and Senior Vice President
TENURE
8.1 yrs
Board of Directors Tenure

Average tenure and age of the BeiGene board of directors in years:

4.9
Average Tenure
57
Average Age
  • The tenure for the BeiGene board of directors is about average.
Board of Directors

John Oyler

TITLE
Co-Founder
COMPENSATION
$10M
AGE
50

Xiaodong Wang

TITLE
Co-Founder
COMPENSATION
$3M
AGE
55
TENURE
7.8 yrs

Steve Young

TITLE
Acting Head of Medicinal Chemistry and Member of Scientific Advisory Board

Donald Glazer

TITLE
Independent Director
COMPENSATION
$14K
AGE
74
TENURE
5.8 yrs

Michael Yi

TITLE
Independent Director
AGE
46
TENURE
4.1 yrs

Thomas Malley

TITLE
Independent Director
COMPENSATION
$716K
AGE
49
TENURE
2.8 yrs

Ron Levy

TITLE
Member of Scientific Advisory Board

Neal Rosen

TITLE
Member of Scientific Advisory Board
AGE
68

David Schenkein

TITLE
Member of Scientific Advisory Board
AGE
61

Charles Sawyers

TITLE
Member of Scientific Advisory Board
AGE
59
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Start End Shares Max Price (€) Value (€)
X
Management checks
We assess BeiGene's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. BeiGene has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

External News
Loading...
Simply Wall St News

Company Info

Map
Description

BeiGene, Ltd. develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer. Its commercial products include ABRAXANE, a chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancer; REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma in combination with dexamethasone; and VIDAZA, a pyrimidine nucleoside analog for the treatment of intermediate-2 and myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia with 20% to 30% blasts and multi-lineage dysplasia. The company’s clinical stage drug candidates include BGB-3111, a small molecule Bruton’s tyrosine kinase (BTK) inhibitor for the treatment of lymphomas; BGB-A317, a humanized monoclonal antibody for solid and hematological cancers; BGB-290, a small molecule inhibitor of PARP1 and PARP2 for the treatment of homologous recombination deficient cancers; BGB-283, a small molecule RAF dimer inhibitor to treat cancers with aberrations in the mitogen-activated protein kinase pathway; BGB-A333, an humanized monoclonal antibody for the immune checkpoint receptor ligand PD-L1; and MGCD-0516, a multi-kinase inhibitor. Its preclinical programs consists of therapies and immuno-oncology agents, including an additional RAF dimer inhibitor, a TIM-3 cell surface protein monoclonal antibody, and a BTK inhibitor for non-oncology indications. The company has strategic collaborations with Celgene Corporation to research and develop BeiGene, Ltd.’s investigational anti-programmed cell death protein 1 inhibitor, BGB-A317; Merck KGaA to research and develop on BGB-290 and BGB-283; and MEI Pharma, Inc. to evaluate the safety and efficacy of ME-401, an investigational PI3K delta inhibitor in combination with BeiGene’s zanubrutinib, an investigational BTK inhibitor for the treatment of patients with B-cell malignancies. BeiGene, Ltd. was founded in 2010 and is based in George Town, the Cayman Islands.

Details
Name: BeiGene, Ltd.
49B
Exchange: BST
Founded: 2010
$6,343,187,772
59,327,456
Website: http://www.beigene.com
Address: BeiGene, Ltd.
94 Solaris Avenue,
Camana Bay,
George Town,
Grand Cayman, KY1-1108,
Cayman Islands
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS BGNE SPON ADS EACH REPR 13 ORD Nasdaq Global Select US USD 03. Feb 2016
DB 49BA SPON ADS EACH REPR 13 ORD Deutsche Boerse AG DE EUR 03. Feb 2016
BMV BGNE N SPON ADS EACH REPR 13 ORD Bolsa Mexicana de Valores MX MXN 03. Feb 2016
DB 49B USD0.0001 Deutsche Boerse AG DE EUR 08. Aug 2018
BST 49B USD0.0001 Boerse-Stuttgart DE EUR 08. Aug 2018
SEHK 6160 USD0.0001 The Stock Exchange of Hong Kong Ltd. HK HKD 08. Aug 2018
Number of employees
Current staff
Staff numbers
1,700
BeiGene employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2018/11/12 18:55
End of day share price update: 2018/08/15 00:00
Last estimates confirmation: 2018/11/10
Last earnings filing: 2018/11/08
Last earnings reported: 2018/09/30
Last annual earnings reported: 2017/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.